Financial Disclosure in Clinical Trials: What Form FDA 3455 Really Covers
Financial conflicts of interest can quietly undermine the credibility of clinical trial data. If an investigator holds stock in the sponsor, owns a patent on the drug being tested, or receives payments tied to the study's outcome, there is a legitimate question about whether the results can be trusted. The FDA's answer is transparency. Sponsors and investigators are required to disclose financial interests that could bias study outcomes, and the agency uses that information to decide whether a study's results are reliable.
The Clarity Clinical Solutions training module on financial disclosure walks through the regulatory framework, the key definitions, and the practical work of completing disclosure forms correctly. Without this process, the whole clinical research enterprise risks losing credibility with regulators, physicians, and patients.
The legal foundation: 21 CFR Part 54
The authority for financial disclosure sits in 21 CFR Part 54, "Financial Disclosure by Clinical Investigators" (21 CFR Part 54). The regulation requires applicants submitting a marketing application, such as an NDA, BLA, or PMA, to disclose the financial interests of the clinical investigators who conducted the covered studies. The rule applies to every investigator who participated in studies submitted in support of the application's safety and efficacy claims.
The FDA can refuse to file an application if the financial disclosure information is incomplete or missing. That is a harsh outcome, but it is exactly why sponsors treat disclosure as a serious operational process rather than paperwork to be chased down at the end.
The FDA's guidance on financial disclosure walks through the regulation in practical terms, including how sponsors should identify covered investigators and collect the required information (FDA Guidance: Financial Disclosure by Clinical Investigators).
Who has to disclose
Financial disclosure requirements apply to all clinical investigators who participated in studies submitted with a marketing application: the principal investigator and every sub-investigator who made significant contributions to the study. The definition extends further than the people who sign the consent form. The financial interests of each investigator's spouse and dependent children are imputed to the investigator, so those must be captured too.
Timing matters. Sponsors must identify each covered investigator and collect disclosure information before or during the study, not after data collection wraps up. Waiting until the end defeats the purpose.
What counts as a disclosable interest
The regulation names specific categories of financial interests that must be disclosed. Compensation from the sponsor that could be affected by the study's outcome, including milestone payments and royalties. Proprietary interests in the investigational product, such as patents, trademarks, or licensing agreements. Significant equity interests in the sponsor, including stock or stock options valued at over $50,000. And payments received from the sponsor during the past year exceeding $25,000, excluding the cost of conducting the study itself.
Those thresholds are set out in the regulation itself, which is one reason the process is so standardized. The definitions also create the most common mistakes: incomplete investigator lists, inaccurate valuation of equity interests, and confusion about what counts as a disclosable payment.
Form FDA 3455 does the collecting
Form FDA 3455, titled "Financial Disclosure by Clinical Investigators," is the standard document used to collect this information (Form FDA 3455). The form captures the investigator's identifying information, the study details, and a detailed listing of any financial arrangements with the sponsor. The investigator must certify the accuracy of the information and sign. Sponsors use the collected forms to prepare a summary for the FDA at the time of the marketing application.
Sponsors should collect the form before the investigator begins study activities, or as soon as financial interests become known. The requirement does not stop there. Investigators must update their disclosure throughout the study and for one year after completion. Late discovery of undisclosed interests can delay regulatory review and raise questions about data integrity.
When something is disclosed
Disclosure is not an automatic disqualifier. When a financial interest is reported, the sponsor assesses whether it creates a real risk of bias. The FDA evaluates the disclosed information and decides whether the data from that investigator's site remains acceptable. The possible outcomes range from accepting the data despite the interest, to requesting additional analyses, to excluding the site's data from the marketing application entirely.
Sponsors should document their mitigation plan and give the FDA enough information to make an independent judgment about the conflict's impact.
Common mistakes
The recurring errors in financial disclosure follow a pattern. Sponsors leave sub-investigators off the list. They misvalue equity interests. They misunderstand what counts as a disclosable payment. They collect disclosure forms after study data collection has begun, which undermines the prospective nature of the requirement. And they fail to collect updated disclosures from investigators who received additional payments during the study. Each of these mistakes is avoidable with a structured process.
Consequences of getting it wrong
Failure to comply carries real consequences. The FDA may refuse to file the marketing application, delaying product approval and costing the sponsor time and revenue. In cases of deliberate concealment, the FDA can pursue enforcement actions including civil monetary penalties and criminal prosecution. For investigators, non-compliance can result in disqualification from receiving investigational products.
Sponsors should build a centralized financial disclosure tracking system that flags collection deadlines, monitors for changes, and generates audit trails. Train clinical operations staff on the requirements and integrate disclosure into site initiation visit checklists. Use clear, standardized communication to explain to investigators what must be disclosed and why. Run periodic quality checks on collected forms. And engage with the FDA early if a complex conflict arises. A proactive program prevents last-minute surprises during NDA review.
Global trials, same rules
For global trials that will be submitted to the FDA, US financial disclosure requirements apply no matter where the study ran. That creates challenges in countries where disclosure norms differ. Forms need translation. Cultural sensitivities around discussing personal finances have to be handled carefully. Compensation structures vary. Sponsors should build these considerations into country-specific feasibility assessments and investigator selection from the start.
The bottom line
Financial disclosure under 21 CFR Part 54 protects trial integrity by identifying potential biases before they can taint a submission. All investigators and sub-investigators must disclose the specified interests before study activities begin. The thresholds are clear: equity over $50,000 and payments over $25,000 annually. Forms must be collected before enrollment, updated during the study and for one year after, and submitted with the marketing application. Non-compliance can delay FDA review and damage professional reputations. Transparency is the foundation of trustworthy clinical research, and Form FDA 3455 is how that transparency gets documented.
This article is based on the Clarity Clinical Solutions video "Financial Disclosure Form - Why Financial Disclosure Matters." Watch it here: Financial Disclosure Form - Why Financial Disclosure Matters
References
- Clarity Clinical Solutions — "Financial Disclosure Form - Why Financial Disclosure Matters" (framework for this article). https://www.youtube.com/watch?v=xIrKP0sv658
- eCFR — 21 CFR Part 54, Financial Disclosure by Clinical Investigators; the regulation defining disclosure requirements and thresholds. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-54
- FDA — Guidance for Industry: Financial Disclosure by Clinical Investigators; practical guidance on implementing Part 54. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/financial-disclosure-clinical-investigators
- FDA — Form FDA 3455, Financial Disclosure by Clinical Investigators (official form PDF). https://www.fda.gov/media/75452/download